BioPreservation Blog 8/8/2018

The number of applications for BioLife Solutions’ biopreservation reagents continues to grow, and we are pleased to highlight these newest citations:

Habiel, D., Espindola, M., Coelho, A., & Hogaboam, C. Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice. The American Journal of Pathology 2018 Apr; 188(4): 891-903. doi: 10.1016/j.ajpath.2017.12.020

Habiel et. al. provided detailed methods for the creation of humanized models of Idiopathic Pulmonary Fibrosis (IPF) in nonobese diabetic (NOD) SCID IL2Rg-/- (NSG) mice.  Explants from surgical lung biopsy samples were minced and mechanically dissociated.  Red blood cells removed by lysis.  Dissociated cells were frozen in CryoStor® CS10 for later use.  Prior to use, the dissociated cells frozen in CS10 were thawed rapidly, and washed in serum-free medium prior to injection into NSG mice, alone, or combined 1:1 with PKH-26-labeled fibroblasts previously isolated from surgical lung biopsy samples.

 

Baradez, M., Biziato, D., Hassan, E., Marshall, D. Application of Raman Spectroscopy and Univariate Modelling As a Process Analytical Technology for Cell Therapy Bioprocessing.  Med. 2018; 5(47), 1-14. doi:10.3389/fmed.2018.00047

Baradez et. al. applied Raman spectroscopy to real time monitoring for key markers of cell growth and metabolism modeled in a stirred tank bioreactor system producing an autologous T-cell immunotherapy. To prepare the inoculum for the stirred culture system, peripheral blood-derived CD4+ T-cells and CD8+ T-cells were isolated and cryopreserved in CryoStor®CS10.  At time of inoculation, T-cells frozen in CS10 were thawed, washed and resuspended in growth media at a concentration of 1 x 106cells/mL.

 

Aijaz, A., Li, M., Smith, D., Khong, D., LeBlon, C., Fenton, O. S., Olabisi, R. M., Libutti, S., Tischfield, J., Maus, M. V., Deans, R., Barcia, R. N., Anderson, D. G., Ritz, J., Preti, R., Parekkadan, B. Biomanufacturing for clinically advanced cell therapies.  Nature Biomedical Engineering 2018; 2(6), 362-376. doi:10.1038/s41551-018-0246-6

In the review article, Aijaz et. al. present cutting-edge bioprocessing technologies applicable to commercial-scale production of cell therapy products.  Cryopreservation technologies are presented in the section titled “Preservation and supply-chain management.”  The authors noted that non-standardized cryomedia usually differ between labs, may contain additives such as plasma or serum that are not sustainable, and introduce variability,  which is difficult to control. CryoStor is cited as a DMSO-containing cryoprotectant frequently used in the manufacture of cell therapies.

 

BioLife’s solutions are off-the-shelf, defined, protein-free, serum-free, and manufactured according to current Good Manufacturing Practice (cGMP) from USP-grade or higher/multicompendial components.  Make our solution, your solution!

Don’t forget to search our Biopreservation Media Evidence library to find additional citations pertaining to your application. Got questions? Ask the Scientists!

Privacy Preference Center

Necessary

Advertising

Analytics

Other